两种SARI病例定义对老年人流感与COVID-19疫苗效果估计的影响比较
基于VEBIS医院网络2023/24赛季七个欧洲国家数据,采用检测阴性设计比较两种SARI病例定义对≥65岁老年人流感与COVID-19疫苗效果估计的影响。结果显示SARI-CD2在A(H1N1)pdm09和SARS-CoV-2中信号更高,尤其≥80岁和接种≥60天后,但95%CI重叠;A(H3N2)、65-79岁和接种14-60天时VE相似。
要点
- SARI-CD2较CD1在A(H1N1)pdm09和SARS-CoV-2中显示更高VE信号,但置信区间重叠。
- ≥80岁人群和接种≥60天后,两种病例定义的VE差异更明显。
- A(H3N2)、65-79岁及接种14-60天时两种定义VE估计相似。
核心结论
- SARI-CD1与CD2对流感A(H3N2)、65-79岁及接种14-60天的VE估计相似。
- SARI-CD2在流感A(H1N1)pdm09和SARS-CoV-2中显示更高VE信号,尤其≥80岁和≥60天,但95%CI重叠。
- 病例定义可能贡献VE变异性,VE研究应明确所用病例定义。
研究设计与样本
- 采用检测阴性设计的医院-based疫苗效果研究,使用VEBIS医院网络2023/24赛季末数据。
- 分析限制在七个使用SARI-CD1招募患者的国家,并构建同时满足SARI-CD2的亚组。
- 病例为RT-PCR阳性流感A(H1N1)pdm09、A(H3N2)或SARS-CoV-2,对照为相应RT-PCR阴性。
- 采用逻辑回归估计≥65岁人群VE,调整国家、发病日期、年龄、性别和慢性病。
主要发现
- 两种病例定义下患者特征和结局相似;SARI-CD1疫苗接种病例略多,对照差异小。
- 流感A(H1N1)pdm09绝对VE差异10%(34% vs 44%),≥80岁差异19%(21% vs 40%),接种60-119天差异18%(4% vs 22%)。
- SARS-CoV-2绝对VE差异总体11%(29% vs 40%),≥80岁11%(33% vs 44%),60-119天12%(34% vs 46%)。
- 其他绝对VE差异均<10%。
关键数值与推荐
- SARI-CD1要求≥1个症状(咳嗽、发热、气短、嗅觉丧失、味觉丧失或味觉障碍)。
- SARI-CD2要求同时有发热和咳嗽。
- 绝对VE差异≥10%被认为有相关性。
临床怎么用
- 在解读老年人流感或COVID-19疫苗效果研究时,应关注其采用的SARI病例定义。
- 对≥80岁和接种≥60天人群,病例定义选择可能影响VE估计,需谨慎比较不同研究结果。
局限性
- 分析仅纳入使用SARI-CD1招募患者的七个国家,可能存在选择偏倚。
- 两种病例定义VE估计的95%CI重叠,不能排除随机误差。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Two severe acute respiratory infection (SARI) case definitions (CDs) are often used in test-negative design (TND) hospital-based vaccine effectiveness (VE) studies. SARI-CD1 requires ≥1 symptom (cough, fever, shortness of breath, anosmia, ageusia, or dysgeusia); SARI-CD2 requires both fever and cough. Using VEBIS hospital network end-of-season 2023/24 data, we compared the effect of these CDs on influenza and COVID-19 VE estimates in Europe. METHODS: Using the TND, we restricted analysis to seven countries recruiting patients using SARI-CD1; we created a subset of SARI patients also meeting SARI-CD2. Cases were RT-PCR-positive for influenza A(H1N1)pdm09, A(H3N2), or SARS-CoV-2; controls were influenza or SARS-CoV-2 RT-PCR-negative. We estimated VE among patients ≥65 years using logistic regression adjusted for country, onset date, age, sex, and chronic conditions. We estimated VE overall, by age group (65-79, ≥80 years) and time since vaccination (14-59, 60-119, ≥120 days). Absolute VE differences ≥10% were considered relevant. RESULTS: Patient characteristics and outcomes were similar across CDs. SARI-CD1 had slightly more vaccinated cases, with little difference in controls between the two CDs. For influenza, the absolute VE difference between SARI-CD1 and SARI-CD2 was 10% for influenza A(H1N1)pdm09 (34% vs 44%), 19% among those aged ≥80 years (21% vs 40%) and 18% at 60-119 days post-vaccination (4% vs 22%). For SARS-CoV-2, absolute VE differences were 11% overall (29% vs 40%), 11% among ≥80 years (33% vs 44%), and 12% at 60-119 days (34% vs 46%). All other absolute VE differences were < 10%. CONCLUSIONS: VE was similar for influenza A(H3N2), adults 65-79 years and 14-60 days post-vaccination. We observed signals of higher VE with SARI-CD2 for influenza A(H1N1)pdm09 and SARS-CoV-2, particularly among adults ≥80 years and ≥ 60 days post-vaccination, although 95% CIs overlapped. These signals suggest CDs may contribute to VE variability and VE studies should clearly indicate CDs used.
引用
- Marques DFP, Howard J, Álvarez ML, et al. Comparing two case definitions for including severe acute respiratory infection patients in influenza and COVID-19 vaccine effectiveness studies among older adults using the test-negative design: VEBIS hospital network, seven European countries, 2023/24. Vaccine. 2026. PMID: 42869874. doi:10.1016/j.vaccine.2026.129234
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。